Comparative Pharmacology
Head-to-head clinical analysis: MECLOFENAMATE SODIUM versus TOLECTIN DS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MECLOFENAMATE SODIUM versus TOLECTIN DS.
MECLOFENAMATE SODIUM vs TOLECTIN DS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Meclofenamate sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis.
50 mg or 100 mg orally three times daily; maximum 400 mg/day.
400 mg orally three times daily; maximum dose 1800 mg/day.
None Documented
None Documented
2-4 hours (terminal half-life; may be prolonged in hepatic impairment or elderly)
Terminal elimination half-life approximately 1 hour; clinical context: requires frequent dosing every 6-8 hours due to short half-life.
Renal (60-70% as metabolites and conjugates), biliary/fecal (20-30%)
Primarily renal, 95% of a dose excreted in urine as glucuronide conjugates and oxidative metabolites; less than 5% fecal.
Category C
Category C
NSAID
NSAID